Imunon Inc (IMNN)
1.33
+0.02
(+1.53%)
USD |
NASDAQ |
May 03, 16:00
1.35
+0.02
(+1.50%)
After-Hours: 20:00
Imunon Research and Development Expense (Quarterly): 3.553M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 3.553M |
| September 30, 2023 | 1.981M |
| June 30, 2023 | 3.134M |
| March 31, 2023 | 2.620M |
| December 31, 2022 | 3.003M |
| September 30, 2022 | 2.409M |
| June 30, 2022 | 3.226M |
| March 31, 2022 | 3.095M |
| December 31, 2021 | 2.986M |
| September 30, 2021 | 2.468M |
| June 30, 2021 | 2.593M |
| March 31, 2021 | 2.572M |
| December 31, 2020 | 2.810M |
| September 30, 2020 | 2.492M |
| June 30, 2020 | 2.991M |
| March 31, 2020 | 3.052M |
| December 31, 2019 | 3.065M |
| September 30, 2019 | 3.674M |
| June 30, 2019 | 3.558M |
| March 31, 2019 | 2.768M |
| December 31, 2018 | 2.344M |
| September 30, 2018 | 2.187M |
| June 30, 2018 | 4.594M |
| March 31, 2018 | 2.741M |
| December 31, 2017 | 3.208M |
| Date | Value |
|---|---|
| September 30, 2017 | 3.349M |
| June 30, 2017 | 3.047M |
| March 31, 2017 | 3.475M |
| December 31, 2016 | 3.620M |
| September 30, 2016 | 4.225M |
| June 30, 2016 | 3.336M |
| March 31, 2016 | 3.441M |
| December 31, 2015 | 3.702M |
| September 30, 2015 | 2.884M |
| June 30, 2015 | 3.568M |
| March 31, 2015 | 4.506M |
| December 31, 2014 | 4.281M |
| September 30, 2014 | 4.630M |
| June 30, 2014 | 3.166M |
| March 31, 2014 | 2.893M |
| December 31, 2013 | 1.869M |
| September 30, 2013 | 2.269M |
| June 30, 2013 | 2.023M |
| March 31, 2013 | 3.203M |
| December 31, 2012 | 3.426M |
| September 30, 2012 | 3.539M |
| June 30, 2012 | 4.112M |
| March 31, 2012 | 4.693M |
| December 31, 2011 | 5.137M |
| September 30, 2011 | 5.414M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
1.981M
Minimum
Sep 2023
3.674M
Maximum
Sep 2019
2.910M
Average
2.991M
Median
Jun 2020
Research and Development Expense (Quarterly) Benchmarks
| Avalo Therapeutics Inc | 1.867M |
| iBio Inc | 1.535M |
| Ocugen Inc | 9.504M |
| Petros Pharmaceuticals Inc | 0.8343M |
| Moderna Inc | 1.063B |